Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple app help pharmacists stop HIV?

NCT ID NCT07683117

Recruiting now Disease control Sponsor: EMPOWERX INC Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests whether a software program called PEPPI makes it easier for pharmacists to offer HIV prevention pills (PEP and PrEP) and for patients to get them. Pharmacists and patients use the software during their normal visits, and researchers compare how well the service works with and without the tool. The goal is to see if technology can boost access to HIV prevention in community pharmacies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PEPPI software (digital tool for pharmacist-prescribed HIV prevention)
What this could lead to
If it works, this software could make HIV prevention pills more accessible by letting pharmacists prescribe them more easily.
What could go wrong
This is a small implementation study, not a test of the drugs themselves. The software may not improve access or be adopted widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACCESS AND LINKAGE TO HEALTHCARE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACCESS AND LINKAGE TO HEALTHCARE HIV PRE-EXPOSURE PROPHYLAXIS HIV PREVENTION TECHNOLOGY USE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • EmpoweRx, Inc

    RECRUITING

    Del Mar, California, 92014, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.